Literature DB >> 16258170

VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase.

Christopher J Robinson1, Barbara Mulloy, John T Gallagher, Sally E Stringer.   

Abstract

The vascular endothelial growth factor (VEGF) family of proteins controls the formation and growth of blood vessels. The most potent and widely expressed isoform, VEGF165, is secreted as a disulfide-linked homodimer with two identical heparin-binding sites. Interactions with heparan sulfate (HS) regulate the diffusion, half-life, and affinity of VEGF165 for its signaling receptors. We have determined a number of key HS structural features that mediate the specific binding of the VEGF165 dimer. Carboxylate groups and 2-O-, 6-O-, and N-sulfation of HS contributed to the strength of the VEGF165 interaction; however, 6-O-sulfates appeared to be particularly important. Cleavage of HS by heparinase, heparitinase, or heparanase severely reduced VEGF165 binding. In contrast, K5 lyase-cleaved HS retained significant VEGF165 affinity, suggesting that binding sites for the growth factor are present within extended stretches of sulfation. Binding studies and molecular modeling demonstrated that an oligosaccharide 6 or 7 residues long was sufficient to fully occupy the heparin-binding site of a VEGF165 monomer. The data presented are consistent with a model whereby the two heparin-binding sites of the VEGF165 dimer interact simultaneously with highly sulfated S-domain regions of the HS chain that can be linked through a stretch of transition sequence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16258170     DOI: 10.1074/jbc.M510760200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  62 in total

1.  The C-terminal fragment of axon guidance molecule Slit3 binds heparin and neutralizes heparin's anticoagulant activity.

Authors:  Eduard Condac; Heather Strachan; Gerardo Gutierrez-Sanchez; Benjamin Brainard; Christina Giese; Christian Heiss; Darryl Johnson; Parastoo Azadi; Carl Bergmann; Ron Orlando; Charles T Esmon; Job Harenberg; Kelley Moremen; Lianchun Wang
Journal:  Glycobiology       Date:  2012-05-28       Impact factor: 4.313

Review 2.  Specific sides to multifaceted glycosaminoglycans are observed in embryonic development.

Authors:  Kenneth L Kramer
Journal:  Semin Cell Dev Biol       Date:  2010-07-03       Impact factor: 7.727

3.  Temporal and functional changes in glycosaminoglycan expression during osteogenesis.

Authors:  Victor Nurcombe; Fuqi Jack Goh; Larisa M Haupt; Sadasivam Murali; Simon M Cool
Journal:  J Mol Histol       Date:  2007-08-03       Impact factor: 2.611

4.  Heparan sulfate regulates VEGF165- and VEGF121-mediated vascular hyperpermeability.

Authors:  Ding Xu; Mark M Fuster; Roger Lawrence; Jeffrey D Esko
Journal:  J Biol Chem       Date:  2010-10-25       Impact factor: 5.157

5.  Method development and analysis of free HS and HS in proteoglycans from pre- and postmenopausal women: evidence for biosynthetic pathway changes in sulfotransferase and sulfatase enzymes.

Authors:  Wei Wei; Rebecca L Miller; Julie A Leary
Journal:  Anal Chem       Date:  2013-05-28       Impact factor: 6.986

6.  WT1-dependent sulfatase expression maintains the normal glomerular filtration barrier.

Authors:  Valérie A Schumacher; Ursula Schlötzer-Schrehardt; S Ananth Karumanchi; Xiaofeng Shi; Joseph Zaia; Stefanie Jeruschke; Dongsheng Zhang; Hermann Pavenstädt; Hermann Pavenstaedt; Astrid Drenckhan; Kerstin Amann; Carrie Ng; Sunny Hartwig; Kar-Hui Ng; Jacqueline Ho; Jordan A Kreidberg; Mary Taglienti; Brigitte Royer-Pokora; Xingbin Ai
Journal:  J Am Soc Nephrol       Date:  2011-06-30       Impact factor: 10.121

7.  Antibody GD3G7 selected against embryonic glycosaminoglycans defines chondroitin sulfate-E domains highly up-regulated in ovarian cancer and involved in vascular endothelial growth factor binding.

Authors:  Gerdy B ten Dam; Els M A van de Westerlo; Anurag Purushothaman; Radu V Stan; Johan Bulten; Fred C G J Sweep; Leon F Massuger; Kazuyuki Sugahara; Toin H van Kuppevelt
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

8.  Engineering insulin-like growth factor-1 for local delivery.

Authors:  Tomotake Tokunou; Rachel Miller; Parth Patwari; Michael E Davis; Vincent F M Segers; Alan J Grodzinsky; Richard T Lee
Journal:  FASEB J       Date:  2008-02-19       Impact factor: 5.191

Review 9.  Diverse cell signaling events modulated by perlecan.

Authors:  John M Whitelock; James Melrose; Renato V Iozzo
Journal:  Biochemistry       Date:  2008-10-01       Impact factor: 3.162

10.  HSPG-binding peptide corresponding to the exon 6a-encoded domain of VEGF inhibits tumor growth by blocking angiogenesis in murine model.

Authors:  Tong-Young Lee; Judah Folkman; Kashi Javaherian
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.